Nektar Therapeutics
NKTRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company carries a $2.53B market cap, placing it firmly in the mid-cap category. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Market Cap
$2.53B
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-6.84
EPS (TTM)
$-6.12
EPS (Fwd)
$-10.84
ROE
-35.8%
ROA
-12.5%
Cash
$684.3M
Total Debt
$135.9M
Free CF
-$134.8M
52W Change
52.8%
Annual Financials
Cash vs Debt
Where NKTR stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, NKTR finished 12.11% above its 150-day moving average ($67.86) and 18.97% above its 200-day moving average ($63.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NKTR overbought or oversold?
At the August 20, 2026 close, NKTR's RSI(14) was 64.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $684.3M in cash and $135.9M in debt, NKTR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$134.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -35.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $92.1M (2022) to $55.2M (2025), a 40% decline worth watching.
With cash comfortably exceeding debt, NKTR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nektar Therapeutics's trajectory.